Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1172027 | 0.87 | ALDH1A1 (0.39) | AKR1C3MEN1TSHRKMT2AALDH1A1 | |
| SCHEMBL1171167 | 0.82 | HRH3 (0.46) | CNR2HRH3PARP1AKR1C3HRH1 | |
| Hydrochloric Acid SCHEMBL1171370 | 0.82 | HRH3 (0.46) | CNR2HRH3PARP1AKR1C3HRH1 | |
| SCHEMBL1171334 | 0.81 | HRH3 (0.51) | CNR2HRH3PARP1AKR1C3HRH1 | |
| SCHEMBL1171280 | 0.80 | CNR2 (0.39) | CNR2HRH3PARP1AKR1C3MEN1 | |
| SCHEMBL1171399 | 0.78 | LMNA (0.40) | CNR2PARP1HRH1PDE10AMCHR1 | |
| SCHEMBL1171216 | 0.76 | HRH3 (0.43) | CNR2HRH3 | |
| SCHEMBL1171273 | 0.76 | PDK2 (0.33) | MEN1KMT2AALDH1A1 | |
| SCHEMBL1171285 | 0.75 | ALDH1A1 (0.34) | MEN1KMT2AALDH1A1 | |
| SCHEMBL1171260 | 0.73 | OGA (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888347-B2 | e.g. 1-(Phenylmethyl)hexahydro-4H-azepin-4-one hydrochloride; neurological and psychiatric disorders; neurodegenerative diseases, cognitive impairments, antiinflammatory agent; Alzheimer's disease, epilepsy, neuritis and back pain, osteoarthritis, rheumatoid arthritis, migraine, Parkinson's disease | GLAXO GROUP LIMITED (GB) | 2011-02-15 | — | — | US | claimed |
| EP-1899350-B1 | PYRAZOLO [3 , 4-D]AZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-05-12 | — | — | EP | claimed |
| US-7888347-B2 | e.g. 1-(Phenylmethyl)hexahydro-4H-azepin-4-one hydrochloride; neurological and psychiatric disorders; neurodegenerative diseases, cognitive impairments, antiinflammatory agent; Alzheimer's disease, epilepsy, neuritis and back pain, osteoarthritis, rheumatoid arthritis, migraine, Parkinson's disease | GLAXO GROUP LIMITED (GB) | 2011-02-15 | — | — | US | disclosed |
| EP-1899350-B1 | PYRAZOLO [3 , 4-D]AZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-05-12 | — | — | EP | disclosed |
| US-20080176832-A1 | Pyrazolo [3,4-D]Azepine Derivatives as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176832-A1 | Pyrazolo [3,4-D]Azepine Derivatives as Histamine H3 Antagonists | HRH3, HRH4, HRH2 | CNR2 133/4885HRH3 1/4885PARP1 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.